Koppert, a leading provider of biological crop protection solutions, and Amoéba, a pioneering company in biocontrol, have entered into a commercial agreement centered around Amoéba’s innovative biofungicide solution. This collaboration follows the recent approval of Amoéba’s biocontrol active substance by the European Union Member States. The biofungicide, based on the lysate of the amoeba Willaertia magna C2c Maky, is set to launch in early 2026.
Multi-Crop, Multi-Country Distribution
The agreement grants Koppert exclusive distribution rights for five years for this biocontrol product. It targets vines and vegetable crops grown both in greenhouses and open fields across 18 European countries, including France, the Netherlands, Germany, and Italy, as well as in the United States. Koppert will distribute the biofungicide under its own brand name. Additionally, the two companies will explore the potential launch of the product in Brazil.
Production of the biofungicide will be carried out at Amoéba’s site in Chassieu, France, and through Contract Development Manufacturing Organizations (CDMO) partners. Koppert and Amoéba will assess future production plans based on operational feedback and projected commercial scale-up.
New Opportunities for Co-Development
Beyond the distribution agreement, Koppert and Amoéba will also engage in discussions to co-develop new biofungicide solutions for the crops covered by this agreement. By combining their respective product ranges and complementary expertise, the companies aim to deliver more effective and sustainable biological solutions that meet growers’ needs and support healthier crops. These solutions are expected to have strong market potential and significant growth opportunities in the coming years.
Leaders’ Statements
Martin Koppert, Chief Business Officer of Koppert, said: “This agreement is a significant step forward in expanding our portfolio of innovative biological solutions. The new biofungicide solution is an exciting addition that aligns perfectly with our mission to support growers with sustainable and effective crop protection tools. We look forward to a successful collaboration with Amoéba, bringing the benefits of this breakthrough technology to farmers worldwide.”
Jean-François Doucet, Chief Executive Officer of Amoéba, said: “The signing of this commercial agreement with the world leader in biocontrol is a key moment in the history of Amoéba. The discussions over the last few months have been very fruitful, and we are delighted to have reached a mutually beneficial agreement. This agreement once again demonstrates the potential and promising prospects of our biofungicide solution. We now look forward to working together.”
Benoît Villers, Chairman of the Board of Directors of Amoéba, said: “We are very pleased to sign this agreement with Koppert, with whom we share many common values and the desire to offer healthy products to the agricultural world. This is a major step forward for Amoéba, which is finally demonstrating the full commercial potential of its biofungicide solution after many years of research and development. The value creation resulting from this agreement will be highly satisfactory for Amoéba, and we can look to the future with confidence and ambition. We can now look calmly at new opportunities to strengthen our financial resources in order to support our industrial and commercial expansion in the interests of all our shareholders.”
